Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04536272
Other study ID # 201900659
Secondary ID 8480180147969201
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 1, 2020
Est. completion date March 1, 2024

Study information

Verified date October 2021
Source University Medical Center Groningen
Contact O. van Minnen
Phone +31503616161
Email o.van.minnen@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.


Description:

Rationale: ECMO treatment has a mortality of 38%, for a large part treatment related due to complications. The most feared complication is ischemic stroke for which heparin is administered with an aPTT target 2.0-2.5 times baseline (approximately 60-75 sec). However, there is no relation between aPTT and the occurrence of stroke (1.2%), but there is a relation with the much more frequent occurrence of bleeding complications (55%) and blood transfusion. Both are strongly related to outcome. Objective: Our objective is to study if reduced anticoagulation targets diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome. Study design: Three-arm non-inferiority RCT. Study population: All adult Dutch patients treated with ECMO during the 30 months of the study. Intervention: Randomization between heparin administration with a target of 2-2.5 times baseline aPTT (usual care, about 60-75 sec.), 1.5-2.0 times baseline aPTT (45-60 sec.) or low molecular weight heparin (LMWH) guided by weight and renal function. Main study parameters/endpoints: The primary outcome parameter is a combined endpoint consisting of: 1) major bleeding including hemorrhagic stroke according to the ELSO definitions; 2) severe thromboembolic complication defined as ischemic stroke, limb ischemia (not related with distal perfusion catheter), or acute pump failure with emergency exchange; 3) mortality at 6 months. Secondary outcome parameters are: 1) blood transfusions; 2) health related quality of life (HR-QoL) at 6 months; 3) exchange of the membrane oxygenator; 4) vessel thrombosis after ECMO removal detected by echography; 5) pulmonary embolism; 6) costs; 7) the individual components of the composite outcome; and 8) all thromboembolic complications combined. Expected outcomes: We expect that with a target of 1.5-2.0x baseline aPTT or with LMWH the primary composite endpoint will be reached in 60% of patients compared to 70% in usual care. To show non-inferiority with a significance level (alpha) of 5%, power of 80% and a non-inferiority limit (delta) of 7.5% the corresponding sample size is 91 patients per group. In other words, if there is a true difference in favor of the experimental treatment of 10%, then 91 patients per group are required to be 80% sure that the upper limit of a one-sided 95% confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a difference in favor of the standard group of more than 7.5%. To compensate for a lower effect and drop-outs 330 patients will be enrolled. Apart from anticoagulation targets, treatment will be as usual so study participation will not lead to a burden for the patient, e.g. no extra blood sampling, tests or visits. After 6 months the patients will be contacted for a short questionnaire to measure health-related quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 330
Est. completion date March 1, 2024
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ECMO treatment during the study period in one of the participating centers - Age above 18 years - Written informed consent Exclusion Criteria: - Patients in whom the ECMO is only used to bridge a procedure - Vital indication for robust anticoagulation (e.g. mechanic valve, pulmonary embolism) - History of heparin induced thrombocytopenia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Heparin
Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
LMWH
Administration of LMWH guided by weight and renal function during ECLS.

Locations

Country Name City State
Netherlands Amsterdam UMC, location AMC Amsterdam Noord-Holland
Netherlands OLVG, location East Amsterdam Noord-Holland
Netherlands University Medical Center Groningen Groningen
Netherlands Leids Universitair Medisch Centrum Leiden Zuid-Holland
Netherlands Maastricht Universitair Medisch Centrum+ Maastricht Limburg
Netherlands St. Antonius Ziekenhuis Nieuwegein Utrecht
Netherlands Radboud UMC Nijmegen Gelderland
Netherlands Erasmus MC Rotterdam Zuid-Holland
Netherlands Isala Clinics Zwolle Overijssel

Sponsors (9)

Lead Sponsor Collaborator
University Medical Center Groningen Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Isala, Leiden University Medical Center, OLVG, Radboud University, St. Antonius Hospital, ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hemorrhagic complications Severe hemorrhagic complications will be registered according to the Extracorporeal Life Support Organization (ELSO) definitions for major bleeding and is defined as clinically overt bleeding with a decrease in hemoglobin of at least 1,24 mmol/L (2 g/dl)/24 hours, or a transfusion requirement of = 3 EH RBC over that same time period. Bleeding that is retroperitoneal, pulmonary or involves the central nervous system, or bleeding that requires surgical intervention is also considered major bleeding. Through ECLS completion, an average of 14 days
Primary Severe thromboembolic complications Severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure Through ECLS completion, an average of 14 days
Primary Mortality Mortality at 6 months 6 months after ECLS
Secondary Number of blood transfusions Number of blood transfusions during ECLS Through ECLS completion, an average of 14 days
Secondary Quality of life at 6 months Quality of life (HR-QoL) measured 6 months after decannulation from ECMO 6 months after ECLS
Secondary Exchange of the membrane oxygenator Number of echanges of the membrane oxygenator during ECLS Through ECLS completion, an average of 14 days
Secondary Vessel thrombosis after ECLS removal Vessel thrombosis after ECLS removal detected by echography After ECLS completion, an average of 14 days
Secondary Cost- effectiveness Cost- effectiveness will be based on reduced costs of blood transfusions and interventions for bleeding (e.g. surgery, interventional radiology) as well as improved outcome. All medical cost items expected to be affected by the ECMO therapy will be measured and valued according to the Dutch standard guidelines for economic evaluations, e.g. blood transfusion, number of ECMO replacements, surgery, and hospital length of stay. 6 months after ECLS
Secondary Pulmonary embolism The occurrence of Pulmonary embolism during ECLS Through ECLS completion, an average of 14 days
Secondary All thromboembolic complications combined The occurrence of all thromboembolic complications combined during ECLS Through ECLS completion, an average of 14 days
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy